There is no confirmed treatment that directly interferes with the disease process. Cosmetic surgery to remove excessive skin has been used to improve aesthetic appearance in<unk>  patients but because of the non-life-threatening nature of these symptoms, should be used with caution. One of the most critical symptom of<unk>  is choroidal neovascularization which can lead to deterioration of central vision. Photodynamic therapy has been used as a treatment, but this has been replaced with endothelial growth factor (VEGF) inhibitors (such as bevacizumab, ranibizumab, and aflibercept) with efficacy similar to their use in treatment of age-related macular degeneration. To limit cardiovascular symptoms, reduction of cardiovascular risk factors through lifestyle changes is recommended. Generally clinicians recommend avoidance of non-steroidal anti-inflammatory drugs (NSAIDS) that increase bleeding risk, such as aspirin, and ibuprofen to prevent eye and gastrointestinal bleeding. Formerly, dietary restriction of calcium was tried with no benefit, and in fact accelerated mineralization in mice. There are a number of potential treatments that are currently being tested or have just undergone testing including magnesium, etidronate, PPi, and tissue-nonspecific alkaline phosphatase inhibitors. Given that ABCC6 heterozygous mutations result in few symptoms of<unk> , this disease is a candidate for gene therapy. Some initial proof-of-principle experiments have been done in mice that have relieved some of symptoms of<unk> , but as with all gene therapy treatments, there are many hurdles that must be over come including insuring that the treatment will be long-lasting and reducing the risk of insertional mutagenesis and severe immune reactions.
Pseudoxanthoma elasticum
Nodular lichen myxedematosus
Keratosis pilaris
Erythrokeratodermia variabilis
Keratosis pilaris atrophicans
Dystrophic calcinosis cutis
Granuloma annulare
Dermatosis neglecta